Topics

Mucinex®D | Mucinex D [Dispensing Solutions Inc.] | BioPortfolio

11:54 EST 27th January 2019 | BioPortfolio
Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Drug Facts

Active ingredients (in each extended-release bi-layer tablet) Purpose
Guaifenesin 600 mg Expectorant
Pseudoephedrine HCl 60 mg Nasal Decongestant

Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product.

Ask a doctor before use if you have

When using this product

Stop use and ask a doctor if

If pregnant or breast-feeding, ask a health professional before use.

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.

carbomer 934P, NF; FD&C yellow #6 aluminum lake; hypromellose, USP; magnesium stearate, NF; microcrystalline cellulose, NF; sodium starch glycolate, NF

Mucinex®D is supplied by Dispensing Solutions Inc. as follows:

This product was:

Distributed by: Reckitt Benckiser Inc. Parsippany, NJ 07054-0224

And Relabeled By:

Dispensing Solutions Inc. 3000 West Warner Ave Santa Ana, CA 92704 United States

NDC Strength Quantity/Form Color Source NDC
68258-3035-1 600 mg / 60 mg 18 Tablets WHITE 63824-057-18

NDC 68258-3035-1

Mucinex®D

600 mg guaifenesin & 60 mg pseudoephedrine HCl extended-release bi-layer tablets

EXPECTORANT & NASAL DECONGESTANT

12 HOUR

NEW LOOK- SAME RELIEF

Thins And Loosens Mucus

Clears Nasal/Sinus Congestion

18 EXTENDED-RELEASE BI-LAYER TABLETS

Manufacturer

Dispensing Solutions Inc.

Active Ingredients

Source

Drugs and Medications [0 Results]

None

Clinical Trials [11 Associated Clinical Trials listed on BioPortfolio]

Mucinex Cold Study

This is a multicenter, randomized, blinded, placebo-controlled study of Mucinex in patients with colds. Patients will receive 7 days of treatment with either Mucinex or placebo. The stud...

Study to Evaluate the Pharmacokinetics of Mucinex® 1200 mg Extended-Release Tablet

Characterize and assess PK of guaifenesin in Mucinex® 1200 mg ER Bi-Layer Tablet

Mucinex® ER 600 mg Bi-Layer Tablet Fed and Fasted

Determine and compare the plasma concentrations of Mucinex® Extended Release (ER) 600 mg bi-layer tablet in normal healthy volunteers in fed and fasting conditions

Phase 4 Study - Mucinex D as Adjunct Therapy

The objective of the study is to evaluate the safety and efficacy of Mucinex D tablets in providing symptom relief when administered as an adjunct to antibiotic therapy in patients with ac...

Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung

The purpose of this research study is to test the ability of Mucinex, an oral, over-the-counter, FDA approved expectorant) to stimulate the clearance of inhaled particles from the subject'...

PubMed Articles [0 Results]

None

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Depression
Depression is a serious mental health condition, where sad feelings carry on for weeks or months and interfere with your life. The symptoms include feeling unhappy most of the time (but may feel a little better in the evenings), loosing interest in lif...

Psychiatry
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...


Drugs and Medication Quicklinks


Searches Linking to this Drug Record